On October 15, 2020 GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE) technology reported its abstract "GTB-3550 TriKE for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation At Initial Dose Cohorts" has been selected by the Program Committee for presentation in an Oral Session at the 62nd American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition as detailed below (Press release, GT Biopharma, OCT 15, 2020, View Source [SID1234568505]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Session Name: 704. Immunotherapies: Beyond T to NK
Session Date: Saturday, December 5, 2020
Session Time: 7:30 AM – 9:00 AM
Presentation Time: 8:00 AM
The ASH (Free ASH Whitepaper) Annual Meeting & Exposition is the premier event in malignant and non-malignant hematology. ASH (Free ASH Whitepaper) has more than 18,000 members from nearly 100 countries. ASH (Free ASH Whitepaper) is the world’s largest professional society serving both clinicians and scientists around the world who are working to conquer blood diseases.
In addition to the presentation, your abstract will also be published online in November supplemental issue of the journal Blood. First publication will be in the online ASH (Free ASH Whitepaper) meeting program on November 5, 2020.
Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented "we are pleased to have the opportunity to present our interim results for GTB-3550 TriKE for the treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory/Relapsed Acute Myeloid Leukemia (AML) patients."